Starpharma Holdings Limited (ASX:SPL): How Does Fresh Funding Support Its Oncology Pipeline?

Aditi Sarkar

28 October 2026 08:49 PM AEDT

Starpharma Holdings Limited (ASX:SPL): How Does Fresh Funding Support Its Oncology Pipeline?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

An August entitlement offer raised $32 million before costs, with funds allocated to oncology development.
At 30 September 2026, Starpharma reported $34.4 million in cash and later received a $3.5 million research tax incentive.
The DEP HER2-Lu program advanced through a European clinical trial application and manufacturing preparation.
Starpharma increased its Petalion Therapeutics ownership to 66% in October 2026.
FY26 revenue included a substantial upfront licence payment, while the company continued to report a net loss.

Starpharma Holdings Limited (ASX:SPL) develops dendrimer-based drug delivery technology, with a current emphasis on targeted oncology therapies and its DEP platform. Recent disclosures have centred on a completed equity raising, preparations for a first-in-human radiopharmaceutical study and a larger interest in a separate cancer research program.

September Quarter Cash Position and Clinical Preparation

In its quarterly activities report released on 22 October 2026, Starpharma Holdings (ASX:SPL) reported cash of $34.4 million at 30 September 2026. It also reported a pro forma cash position of $37.9 million after including a $3.5 million research and development tax incentive received on 22 October. Customer receipts for the September quarter totalled $1.0 million, including an AUD $0.5 million licensing option fee from its Radiopharm collaboration. Research and development costs during the quarter were $2.6 million, while staffing costs were $3.3 million.

Starpharma Holdings (ASX:SPL) submitted a Clinical Trial Application in Europe for the planned first-in-human Phase 1 study of DEP HER2-Lu in patients with HER2-expressing cancers. The company also completed manufacture of non-radiolabelled clinical material and continued radiolabelling validation and site preparation. Regulatory approval and site-start-up work remain prerequisites for first-patient dosing.

Entitlement Offer and FY26 Financial Results

In August 2026, Starpharma Holdings (ASX:SPL) completed a fully underwritten $32 million entitlement offer. The company reported net proceeds of approximately $30 million, with the financing intended to support DEP HER2-Lu clinical development and additional targeted oncology assets. Its October investor presentation indicated that the proceeds extended the expected cash runway into FY28.

For the financial year ended 30 June 2026, Starpharma Holdings (ASX:SPL) reported revenue of $12.0 million, compared with $4.9 million in FY25. An $8.3 million upfront payment under the Genentech collaboration accounted for most of FY26 revenue. The reported annual loss narrowed to $7.5 million from $10.0 million, although research and product development expenditure increased to $11.1 million from $8.4 million. Cash at 30 June was $11.0 million, before the entitlement offer proceeds arrived.

Petalion Ownership and Pipeline Development

On 20 October 2026, Starpharma Holdings (ASX:SPL) announced that its interest in Petalion Therapeutics had risen from 22.5% to 66%. Petalion is developing a fibroblast activation protein-targeted dendrimer-drug conjugate. Under the arrangement, Starpharma will contribute up to AUD $5.0 million, including AUD $3.0 million in cash and up to AUD $2.0 million in research services. Medicxi retained a 30% interest, while advisers hold the remaining 4%.

Clinical, Funding and Execution Considerations

The lead radiopharmaceutical candidate has not yet demonstrated clinical outcomes in the planned Phase 1 study. Trial approvals, manufacturing controls, recruitment, safety findings and access to specialist radioactive materials can affect development timing. The Petalion program remains earlier-stage research, and additional spending will precede any potential clinical progress. Starpharma’s licence and partnership revenue can vary with contractual milestones, while future research requirements may affect its cash runway.

Key Insights

Starpharma Holdings (ASX:SPL) entered FY27 with a larger cash balance following its entitlement offer and reported progress toward clinical testing of DEP HER2-Lu. Its October disclosures also added majority control of Petalion. Regulatory decisions and clinical findings remain important milestones.

FAQs

Q: What did Starpharma report for FY26?

A: Revenue was $12.0 million and the reported loss was $7.5 million for the year ended 30 June 2026.

Q: How much cash did Starpharma hold at September quarter-end?

A: It reported $34.4 million at 30 September 2026, before a subsequent $3.5 million tax incentive receipt.

Q: What is DEP HER2-Lu?

A: It is a planned first-in-human radiopharmaceutical program targeting HER2-expressing cancers.

Q: What ownership does Starpharma have in Petalion?

A: The company announced a 66% interest on 20 October 2026.

Q: Does the entitlement offer eliminate future funding risk?

A: No. The company indicated an expected cash runway into FY28, subject to spending and development outcomes.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.